^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    4d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Apr 2029 --> Jul 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    6d
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov)
    P1, N=82, Recruiting, Amgen | N=34 --> 82
    Enrollment change
    |
    Imdelltra (tarlatamab-dlle)
    6d
    DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=200, Suspended, Amgen | Recruiting --> Suspended
    Trial suspension
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • YL201
    10d
    Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. (PubMed, Immunotherapy)
    Following three months of maintenance therapy with atezolizumab, new metastatic lesions in the liver and brain developed. Tarlatamab induced complete resolution of the metastatic lesions in the liver and brain, without adverse events attributable to tarlatamab. This case underscores the potential value of delta-like ligand 3-targeted therapy with tarlatamab in metastatic digestive neuroendocrine carcinoma, a rare and highly aggressive malignancy with few effective treatment options.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Tecentriq (atezolizumab) • Imdelltra (tarlatamab-dlle)
    10d
    Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer. (PubMed, J Thorac Oncol)
    Acquired resistance to tarlatamab plus anti-PD-1 in SCLC was associated with low DLL3 antigen expression particularly in the setting of phenotypic switch to a non-small cell lung cancer morphology and an increasingly immunosuppressive TME. Therefore, combination strategies that incorporate immune checkpoint blockade or myeloid-targeted therapies may be warranted to enhance treatment outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • DLL3 (Delta Like Canonical Notch Ligand 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MRC1 (Mannose Receptor C-Type 1) • SYP (Synaptophysin)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)
    22d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    22d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=262, Recruiting, Merck Sharp & Dohme LLC | N=59 --> 262
    Enrollment change
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    23d
    Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report. (PubMed, Cureus)
    In this case, the peripheral blood lymphocyte count decreased, and the interleukin-6 level was markedly elevated, which was thought to reflect T-cell accumulation in the tumor. These trends in the blood tests may be useful in easily differentiating PsPD from true progressive disease during tarlatamab treatment.
    Journal
    |
    IL6 (Interleukin 6)
    |
    Imdelltra (tarlatamab-dlle)
    23d
    AIO-TRK-0624: A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) (2025-522437-65-00)
    P1/2, N=57, Recruiting, AIO-Studien gGmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imdelltra (tarlatamab-dlle)
    26d
    SCLC Tarlatamab Blood Collection (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Duke University
    New trial
    |
    Imdelltra (tarlatamab-dlle)
    27d
    DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov)
    P2, N=92, Active, not recruiting, Amgen | N=69 --> 92
    Enrollment change
    |
    Imdelltra (tarlatamab-dlle)
    30d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=59, Recruiting, Merck Sharp & Dohme LLC | N=40 --> 59
    Enrollment change
    |
    CD276 (CD276 Molecule)
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)